Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 8/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | BACE1 | P56817 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | FNTA | P49354 | 1/20 | 0.37 |
| ▸ | FNTB | P49356 | 1/20 | 0.37 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21066907 | 1.00 | EPHX1 (0.40) | EPHX1DRD2ACHEBACE1MEN1 | |
| SCHEMBL23005327 | 0.96 | CHRM2 (0.41) | EPHX1DRD2MEN1GAAKMT2A | |
| SCHEMBL23005328 | 0.96 | CHRM2 (0.41) | EPHX1DRD2MEN1GAAKMT2A | |
| SCHEMBL23005331 | 0.81 | EPHX1 (0.44) | EPHX1DRD2ACHEBACE1MEN1 | |
| SCHEMBL23005330 | 0.81 | EPHX1 (0.44) | EPHX1DRD2ACHEBACE1MEN1 | |
| SCHEMBL19965194 | 0.81 | F2 (0.48) | EPHX1DRD2ACHEBACE1CNR2 | |
| SCHEMBL28938876 | 0.81 | F2 (0.48) | EPHX1DRD2ACHEBACE1CNR2 | |
| SCHEMBL21066910 | 0.79 | CTSK (0.38) | — | |
| SCHEMBL21066908 | 0.79 | CTSK (0.38) | — | |
| SCHEMBL28520869 | 0.78 | EPHX1 (0.43) | EPHX1DRD2ACHEBACE1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12465582-B2 | (S)-2-amino-6-((3-aminopropyl)amino)hexanoic acid (APL) for use in the treatment of non-alcoholic steatohepatitis (NASH), liver inflammation, hepatocellular ballooning, liver fibrosis and steatosis | Temple University—Of the Commonwealth System of Higher Education (US) | 2025-11-11 | — | — | US | disclosed |
| EP-4595969-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | Temple University Of The Commonwealth System Of Higher Education (US) | 2025-08-06 | — | — | EP | disclosed |
| EP-3509575-B1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | UNIV TEMPLE (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20230172886-A1 | (S)-2-AMINO-6-((3-AMINOPROPYL)AMINO)HEXANOIC ACID (APL) FOR USE IN THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS (NASH), LIVER INFLAMMATION, HEPATOCELLULAR BALLOONING, LIVER FIBROSIS AND STEATOSIS | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2023-06-08 | — | — | US | disclosed |
| US-11596615-B2 | Compositions and methods for treatment of insulin resistance | Temple University—Of the Commonwealth System of Higher Education (US) | 2023-03-07 | — | — | US | disclosed |
| EP-4138812-A1 | (S)-2-AMINO-6-((3-AMINOPROPYL)AMINO)HEXANOIC ACID (APL) FOR USE IN THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS (NASH), LIVER INFLAMMATION, HEPATOCELLULAR BALLOONING, LIVER FIBROSIS AND STEATOSIS | Temple University - Of The Commonwealth System of Higher Education (US) | 2023-03-01 | — | — | EP | disclosed |
| WO-2021217006-A1 | (S)-2-AMINO-6-((3-AMINOPROPYL)AMINO)HEXANOIC ACID (APL) FOR USE IN THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS (NASH), LIVER INFLAMMATION, HEPATOCELLULAR BALLOONING, LIVER FIBROSIS AND STEATOSIS | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2021-10-28 | — | — | WO | disclosed |
| US-20210052532-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2021-02-25 | — | — | US | disclosed |
| US-20210046030-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2021-02-18 | — | — | US | disclosed |
| US-10729670-B2 | Compositions and methods for treatment of insulin resistance | Temple University—Of The Commonwealth Systems Of Higher Education (US) | 2020-08-04 | — | — | US | disclosed |
| US-20190192462-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210052532-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | GPR119, FABP4, SLC2A3 | EPHX1 3242/4885DRD2 3667/4885ACHE 1590/4885 |
| US-11596615-B2 | Compositions and methods for treatment of insulin resistance | GPR119, INSR, IAPP | EPHX1 3824/4885DRD2 3657/4885ACHE 3433/4885 |
| US-10729670-B2 | Compositions and methods for treatment of insulin resistance | GPR119, INSR, IAPP | EPHX1 3824/4885DRD2 3657/4885ACHE 3433/4885 |
| US-20190192462-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | GPR119, INSR, IAPP | EPHX1 3824/4885DRD2 3657/4885ACHE 3433/4885 |
| US-20210046030-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | GPR119, INSR, IAPP | EPHX1 3824/4885DRD2 3657/4885ACHE 3433/4885 |
| US-20230172886-A1 | (S)-2-AMINO-6-((3-AMINOPROPYL)AMINO)HEXANOIC ACID (APL) FOR USE IN THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS (NASH), LIVER INFLAMMATION, HEPATOCELLULAR BALLOONING, LIVER FIBROSIS AND STEATOSIS | FABP1, AADAT, FABP6 | EPHX1 2464/4885DRD2 4779/4885ACHE 3847/4885 |
| US-12465582-B2 | (S)-2-amino-6-((3-aminopropyl)amino)hexanoic acid (APL) for use in the treatment of non-alcoholic steatohepatitis (NASH), liver inflammation, hepatocellular ballooning, liver fibrosis and steatosis | FABP1, AADAT, FABP6 | EPHX1 2464/4885DRD2 4779/4885ACHE 3847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.